Has Keytruda + Inlyta been approved yet?
Keytruda (pembrolizumab) and Inlyta (axitinib) have been approved together for certain advanced kidney cancers, including advanced renal cell carcinoma (RCC). FDA approvals for this combination are based on trial results in previously untreated advanced RCC populations [1].
What cancer type and setting is the Keytruda + Inlyta approval for?
Approvals for Keytruda + Inlyta are tied to specific RCC stages and treatment settings (for example, first-line treatment of advanced RCC, depending on the exact indication language in the label) [1]. The precise eligibility criteria come from the approved FDA indication in the prescribing information and may differ by risk group or disease stage [1].
Which countries’ regulators approved it, and when?
Regulatory timing and the exact indication scope can vary by region (for example, FDA vs. other agencies). In the U.S., the combination’s approval status and the most current label wording can be checked through the FDA approval history and the current prescribing information [1].
What evidence supports the approval?
FDA approvals for Keytruda + Inlyta are grounded in clinical trial outcomes in advanced RCC, including measures such as overall survival and progression-free outcomes, depending on the trial and patient population described in the approval materials [1].
What’s the dosing pattern if you’re using the approved combination?
The dosing schedule depends on the specific FDA-labeled regimen. In general, Keytruda is given intravenously at an interval specified on the label, while Inlyta is taken orally twice daily, with adjustments based on tolerability and lab values as directed by the prescribing information [1].
Where can you confirm the exact approved indication wording?
The most reliable source is the FDA label and approval documentation for Keytruda and Inlyta, which state the exact indication, line of therapy, and eligibility criteria for using the combination [1].
Sources
[1] https://www.accessdata.fda.gov/